Dust attenuation law in JWST galaxies at z = 7-8

Attenuation curves in galaxies depend on dust chemical composition, content, and grain size distribution. Such parameters are related to intrinsic galaxy properties such as metallicity, star formation rate, and stellar age. Due to the lack of observational constraints at high redshift, dust empirical curves measured in the local Universe (e.g. Calzetti and SMC curves) have been employed to describe the dust attenuation at early epochs. We exploit the high sensitivity and spectral resolution of the JWST to constrain the dust attenuation curves in high-z galaxies. Our goals are to check whether dust attenuation curves evolve with redshift and quantify the dependence of the inferred galaxy properties on the assumed dust attenuation law. We develop a modified version of the SED fitting code BAGPIPES by including a detailed dust attenuation curve parametrization. Dust parameters are derived, along with galaxy properties, from the fit to the data from FUV to mm bands. Once applied to three star-forming galaxies at z = 7-8, we find that their attenuation curves differ from local templates. One out of three galaxies shows a characteristic MW bump, typically associated to the presence of small carbonaceous dust grains such as PAHs. This is one of the first evidences suggesting the presence of PAHs in early galaxies. Galaxy properties such as stellar mass and SFR inferred from SED fitting are strongly affected by the assumed attenuation curve, though the adopted star formation history also plays a major role. Our results highlight the importance of accounting for the potential diversity of dust attenuation laws when analyzing the properties of galaxies at the EoR, whose dust properties are still poorly understood. The application of our method to a larger sample of galaxies observed with JWST can provide us important insights into the properties of dust and galaxies in the early universe.Comment: 19 pages, 10 figure

The dust attenuation law in z ∼6 quasars

We investigate the attenuation law in $z\sim 6$ quasars by combining cosmological zoom-in hydrodynamical simulations of quasar host galaxies, with multi-frequency radiative transfer calculations. We consider several dust models differing in terms of grain size distributions, dust mass and chemical composition, and compare the resulting synthetic Spectral Energy Distributions (SEDs) with data from bright, early quasars. We show that only dust models with grain size distributions in which small grains ($a < 0.1~\mu$m, corresponding to $\approx 60\%$ of the total dust mass) are selectively removed from the dusty medium provide a good fit to the data. Removal can occur if small grains are efficiently destroyed in quasar environments and/or early dust production preferentially results in large grains. Attenuation curves for these models are close to flat, and consistent with recent data; they correspond to an effective dust-to-metal ratio $f_d \simeq 0.38$, i.e. close to the Milky Way value.STFC ER

A survey of high-z galaxies: serra simulations

We introduce SERRA, a suite of zoom-in high-resolution (1.2 ×104 M⊙, ≃ 25 pc at z = 7.7) cosmological simulations including non-equilibrium chemistry and on-the-fly radiative transfer. The outputs are post-processed to derive galaxy ultraviolet (UV) + far-infrared (FIR) continuum and emission line properties. Results are compared with available multiwavelength data to constrain the physical properties [e.g. star formation rates (SFRs), stellar/gas/dust mass, metallicity] of high-redshift 6 ≲ z ≲ 15 galaxies. This flagship paper focuses on the z = 7.7 sub-sample, including 202 galaxies with stellar mass 107 M⊙ ≲ M⊙ ≲ 5 ×1010 M⊙, and specific star formation rate ranging from sSFR ∼100 Gyr-1 in young, low-mass galaxies to ∼10 Gyr-1 for older, massive ones. At this redshift, SERRA galaxies are typically bursty, i.e. they are located abo v e the Schmidt-Kennicutt relation by a factor κs = 3.03+4.9-1.8, consistent with recent findings for [O III ] and [C II ] emitters at high z. They also show relatively large InfraRed eXcess (IRX = LFIR/LUV) values as a result of their compact/clumpy morphology effectively blocking the stellar UV luminosity. Note that this conclusion might be affected by insufficient spatial resolution at the molecular cloud level. We confirm that early galaxies lie on the standard [C II ] -SFR relation; their observed L[OIII]/L [CII] ≃ 1-10 ratios can be reproduced by a part of the SERRA galaxies without the need of a top-heavy initial mass function and/or anomalous C/O abundances. [O I] line intensities are similar to local ones, making ALMA high-z detections challenging but feasible ( ∼6 h for an SFR of 50 M⊙yr-1)

A survey of high-z galaxies: SERRA simulations

Galaxie

Notulae to the Italian alien vascular flora: 16

In this contribution, new data concerning the distribution of vascular flora alien to Italy are presented. It includes new records and status changes from casual to naturalized for Italy or for Italian administrative regions. Nomenclatural and distribution updates, published elsewhere, and corrections are provided as supplementary material

Sustained seizure freedom with adjunctive brivaracetam in patients with focal onset seizures

The maintenance of seizure control over time is a clinical priority in patients with epilepsy. The aim of this study was to assess the sustained seizure frequency reduction with adjunctive brivaracetam (BRV) in real-world practice. Patients with focal epilepsy prescribed add-on BRV were identified. Study outcomes included sustained seizure freedom and sustained seizure response, defined as a 100% and a ≥50% reduction in baseline seizure frequency that continued without interruption and without BRV withdrawal through the 12-month follow-up. Nine hundred ninety-four patients with a median age of 45 (interquartile range = 32–56) years were included. During the 1-year study period, sustained seizure freedom was achieved by 142 (14.3%) patients, of whom 72 (50.7%) were seizure-free from Day 1 of BRV treatment. Sustained seizure freedom was maintained for ≥6, ≥9, and 12&nbsp;months by 14.3%, 11.9%, and 7.2% of patients from the study cohort. Sustained seizure response was reached by 383 (38.5%) patients; 236 of 383 (61.6%) achieved sustained ≥50% reduction in seizure frequency by Day 1, 94 of 383 (24.5%) by Month 4, and 53 of 383 (13.8%) by Month 7 up to Month 12. Adjunctive BRV was associated with sustained seizure frequency reduction from the first day of treatment in a subset of patients with uncontrolled focal epilepsy

Adjunctive Brivaracetam in Focal Epilepsy: Real-World Evidence from the BRIVAracetam add-on First Italian netwoRk STudy (BRIVAFIRST)

Background: In randomized controlled trials, add-on brivaracetam (BRV) reduced seizure frequency in patients with drug-resistant focal epilepsy. Studies performed in a naturalistic setting are a useful complement to characterize the drug profile. Objective: This multicentre study assessed the effectiveness and tolerability of adjunctive BRV in a large population of patients with focal epilepsy in the context of real-world clinical practice. Methods: The BRIVAFIRST (BRIVAracetam add-on First Italian netwoRk STudy) was a retrospective, multicentre study including adult patients prescribed adjunctive BRV. Patients with focal epilepsy and 12-month follow-up were considered. Main outcomes included the rates of seizure‐freedom, seizure response (≥&nbsp;50% reduction in baseline seizure frequency), and treatment discontinuation. The incidence of adverse events (AEs) was also considered. Analyses by levetiracetam (LEV) status and concomitant use of strong enzyme-inducing antiseizure medications (EiASMs) and sodium channel blockers (SCBs) were performed. Results: A total of 1029 patients with a median age of 45&nbsp;years (33–56) was included. At 12 months, 169 (16.4%) patients were seizure-free and 383 (37.2%) were seizure responders. The rate of seizure freedom was 22.3% in LEV-naive patients, 7.1% in patients with prior LEV use and discontinuation due to insufficient efficacy, and 31.2% in patients with prior LEV use and discontinuation due to AEs (p&nbsp;&lt;&nbsp;0.001); the corresponding values for ≥&nbsp;50% seizure frequency reduction were 47.9%, 29.7%, and 42.8% (p&nbsp;&lt;&nbsp;0.001). There were no statistically significant differences in seizure freedom and seizure response rates by use of strong EiASMs. The rates of seizure freedom (20.0% vs. 16.6%; p&nbsp;=&nbsp;0.341) and seizure response (39.7% vs. 26.9%; p&nbsp;=&nbsp;0.006) were higher in patients receiving SCBs than those not receiving SCBs; 265 (25.8%) patients discontinued BRV. AEs were reported by 30.1% of patients, and were less common in patients treated with BRV and concomitant SCBs than those not treated with SCBs (28.9% vs. 39.8%; p&nbsp;=&nbsp;0.017). Conclusion: The BRIVAFIRST provided real-world evidence on the effectiveness of BRV in patients with focal epilepsy irrespective of LEV history and concomitant ASMs, and suggested favourable therapeutic combinations

How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study

Background: Current guidelines suggest to consider dual antiplatelet therapy (DAPT) continuation for longer than 12 months in selected patients with myocardial infarction (MI). Hypothesis: We sought to assess the criteria used by cardiologists in daily practice to select patients with a history of MI eligible for DAPT continuation beyond 1 year. Methods: We analyzed data from the EYESHOT Post-MI, a prospective, observational, nationwide study aimed to evaluate the management of patients presenting to cardiologists 1 to 3 years from the last MI event. Results: Out of the 1633 post-MI patients enrolled in the study between March and December 2017, 557 (34.1%) were on DAPT at the time of enrolment, and 450 (27.6%) were prescribed DAPT after cardiologist assessment. At multivariate analyses, a percutaneous coronary intervention (PCI) with multiple stents and the presence of peripheral artery disease (PAD) resulted as independent predictors of DAPT continuation, while atrial fibrillation was the only independent predictor of DAPT interruption for patients both at the second and the third year from MI at enrolment and the time of discharge/end of the visit. Conclusions: Risk scores recommended by current guidelines for guiding decisions on DAPT duration are underused and misused in clinical practice. A PCI with multiple stents and a history of PAD resulted as the clinical variables more frequently associated with DAPT continuation beyond 1 year from the index MI

GABAA receptors as molecular targets of general anesthetics: identification of binding sites provides clues to allosteric modulation

PurposeThe purpose of this review is to summarize current knowledge of detailed biochemical evidence for the role of γ-aminobutyric acid type A receptors (GABA(A)-Rs) in the mechanisms of general anesthesia.Principal findingsWith the knowledge that all general anesthetics positively modulate GABA(A)-R-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of amino acid residues in the transmembrane domain that are critical for the drug actions in vitro. Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, αM1-11' and βM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the β/α interface. This position would be appropriate for modulation of agonist channel gating. Overall, available information suggests that these two etomidate binding residues are allosterically coupled to sites of action of steroids, barbiturates, volatile agents, and propofol, but not alcohols. Residue α/βM2-15' is probably not a binding site but allosterically coupled to action of volatile agents, alcohols, and intravenous agents, and α/βM1-(-2') is coupled to action of intravenous agents.ConclusionsEstablishment of a coherent and consistent structural model of the GABA(A)-R lends support to the conclusion that general anesthetics can modulate function by binding to appropriate domains on the protein. Genetic engineering of mice with mutation in some of these GABA(A)-R residues are insensitive to general anesthetics in vivo, suggesting that further analysis of these domains could lead to development of more potent and specific drugs